Previous 10 | Next 10 |
SYDNEY, Australia, June 06, 2023 (GLOBE NEWSWIRE) -- Ai-Media , the leader in technology-driven live captioning, transcription, and translation solutions, is excited to announce its presence at BroadcastAsia in Singapore, where it will unveil its ground-breaking LEXI 3.0 automatic caption...
2023-05-16 14:14:04 ET AIM ImmunoTech Inc. (AIM) Q1 2023 Earnings Conference Call May 16, 2023 08:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Ph.D. Scientific Officer Conference Call Participants James Molloy - Alliance Global ...
2023-05-15 09:28:21 ET AIM ImmunoTech press release ( NYSE: AIM ): Q1 GAAP EPS of -$0.08. As of March 31, 2023, AIM reported cash, cash equivalents and marketable securities of $30.8 million. Based on management’s current expectation, the Company’s cash runwa...
– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter – P...
2023-05-12 13:03:21 ET Alimera Sciences ( ALIM ) is scheduled to announce Q1 earnings results on Monday, May 15th, before market open. The consensus EPS Estimate is -$0.52 (+38.8% Y/Y) and the consensus Revenue Estimate is $12.3M (+3.4% Y/Y). Over the last 3 months, EPS es...
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIMIA ANNOUNCES CLOSING OF BOZZETTO TRANSACTION Canada NewsWire (All figures in Canadian dollars unless otherwise noted) SECOND MAJOR ACQUISITION OF 2023 ESTABLISHES STRONG GROWTH PLATFORM FOR AIMIA TORONTO , May 9, 2023 /CNW/ - Aimia Inc. (TSX: A...
SYDNEY, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Ai-Media , the global leader in professional captioning solutions, is proud to announce the launch of LEXI 3.0 , the new and improved version of its flagship live automatic captioning solution. With cutting-edge enhancements and new feat...
Company’s SAB is comprised of well-established leaders with expertise across biomedical research, academia, and pharmaceutical industry OCALA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”),...
AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE Canada NewsWire In order to be counted at the annual meeting of shareholders, proxies must be received by 10:30 a.m. (Eastern Daylight Time) on April 14, 2023 ...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stoc...